Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric PopulationBusiness Wire • 03/16/21
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna's Next Generation COVID-19 VaccineBusiness Wire • 03/15/21
Moderna's stock gains 1.9% as it begins testing COVID-19 vaccine with easier storage requirementsMarket Watch • 03/15/21
Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines?The Motley Fool • 03/13/21
Moderna, Inc. (MRNA) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 03/11/21